Clinical Trial Update: Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating genotype/phenotype-guided supplementation of tamoxifen with endoxifen in breast cancer and DCIS patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ

Drugs mentioned

• Endoxifen (Endoxifen)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) | Conditions: Breast Cancer, DCIS | Phase 2 | Status: COMPLETED